The Search for Function Much of the promising work on commercial applications of genetics is occurring at small companies. Some are already publicly traded; others might help their larger partners strike it rich. AFFYMETRIX*: SANTA CLARA, CALIF. DNA chips. Deals with Hoffmann-La Roche, Merck, and Glaxo. CADUS*: TARRYTOWN, N.Y. Studying yeast. Deals with SmithKline Beecham, Bristol-Myers Squibb, and Solvay. EXELIXIS: CAMBRIDGE, MASS. Fruit flies. Private co. raised $16 million, IPO expected next year. No announced deals yet. GENSET*: PARIS Strength is in finding regulatory regions for genes. Deals with Synthelabo, Johnson & Johnson. HUMAN GENOME SCIENCES*: ROCKVILLE, MD. Strong sequencing company. Deals with SKB and Merck DGaA. INCYTE*: PALO ALTO, CALIF. Combines huge DNA database with chips. Deals with Pfizer, Upjohn, and 8 others. MILLENNIUM*: CAMBRIDGE, MASS. Gene hunters plus strong functional capabilities. Deals with Hoffmann-LaRoche, Lilly. NEMAPHARM: CAMBRIDGE, MASS. Studying nematodes, now owned by Sequana. Deal with Glaxo. *PUBLICLY TRADED DATA: BW Return to main story

Updated June 15, 1997 by bwwebmaster
Copyright 1997, by The McGraw-Hill Companies Inc. All rights reserved.
Terms of Use